O. A. O'connor Et Al. , "First Multicenter, Randomized Phase 3 Study in Patients (Pts) with Relapsed/Refractory (R/R) Peripheral T-Cell Lymphoma (PTCL): Alisertib (MLN8237) Versus Investigator's Choice (Lumiere trial; NCT01482962)," BLOOD , vol.126, no.23, pp.341, 2015
O'connor, O. A. Et Al. 2015. First Multicenter, Randomized Phase 3 Study in Patients (Pts) with Relapsed/Refractory (R/R) Peripheral T-Cell Lymphoma (PTCL): Alisertib (MLN8237) Versus Investigator's Choice (Lumiere trial; NCT01482962). BLOOD , vol.126, no.23 , 341.
O'connor, O. A., Özcan, M., Jacobsen, E. D., Roncero Vidal, J. M., Trotman, J., Demeter, J., ... Masszi, T.(2015). First Multicenter, Randomized Phase 3 Study in Patients (Pts) with Relapsed/Refractory (R/R) Peripheral T-Cell Lymphoma (PTCL): Alisertib (MLN8237) Versus Investigator's Choice (Lumiere trial; NCT01482962). BLOOD , vol.126, no.23, 341.
O'connor, Owen Et Al. "First Multicenter, Randomized Phase 3 Study in Patients (Pts) with Relapsed/Refractory (R/R) Peripheral T-Cell Lymphoma (PTCL): Alisertib (MLN8237) Versus Investigator's Choice (Lumiere trial; NCT01482962)," BLOOD , vol.126, no.23, 341, 2015
O'connor, Owen A. Et Al. "First Multicenter, Randomized Phase 3 Study in Patients (Pts) with Relapsed/Refractory (R/R) Peripheral T-Cell Lymphoma (PTCL): Alisertib (MLN8237) Versus Investigator's Choice (Lumiere trial; NCT01482962)." BLOOD , vol.126, no.23, pp.341, 2015
O'connor, O. A. Et Al. (2015) . "First Multicenter, Randomized Phase 3 Study in Patients (Pts) with Relapsed/Refractory (R/R) Peripheral T-Cell Lymphoma (PTCL): Alisertib (MLN8237) Versus Investigator's Choice (Lumiere trial; NCT01482962)." BLOOD , vol.126, no.23, p.341.
@article{article, author={Owen A. O'connor Et Al. }, title={First Multicenter, Randomized Phase 3 Study in Patients (Pts) with Relapsed/Refractory (R/R) Peripheral T-Cell Lymphoma (PTCL): Alisertib (MLN8237) Versus Investigator's Choice (Lumiere trial; NCT01482962)}, journal={BLOOD}, year=2015, pages={341} }